Text Size
497 studies found for:    multiple myeloma | Open Studies | multiple myeloma

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Recruiting Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: cyclophosphamide;   Drug: lenalidomide;   Other: laboratory biomarker analysis;   Drug: dexamethasone;   Procedure: quality-of-life assessment
22 Recruiting Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: Group A=30-60 CrCl (mL/min);   Drug: Group B=CrCL<30 mL/min not on dialysis;   Drug: Group C=CrCL<30 mL/min and on dialysis
23 Recruiting S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Myeloma
Interventions: Biological: elotuzumab;   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
24 Recruiting Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: carfilzomib;   Drug: lenalidomide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
25 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Conditions: Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Smoldering Multiple Myeloma;   Lymphoblastic Lymphoma
Intervention:
26 Recruiting Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Conditions: Plasma Cell Dyscrasias;   Monoclonal Gammopathy of Undetermined Significance;   AL Amyloidosis;   Multiple Myeloma
Intervention: Procedure: tissue banking
27 Recruiting Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: MV-NIS;   Drug: cyclophosphamide;   Other: I-123 prior MV-NIS;   Other: I-123 post MV-NIS;   Drug: Liothyronine
28 Unknown † Study of DNA Samples From Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Intervention: Genetic: polymorphism analysis
29 Unknown † Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: melphalan;   Drug: panobinostat
30 Unknown † High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Biological: pegfilgrastim;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
31 Unknown † Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: melphalan;   Drug: pegylated liposomal doxorubicin hydrochloride
32 Unknown † Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: platelet aggregation test
33 Unknown † High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Radiation: yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183
34 Unknown † Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: dexamethasone
35 Unknown † Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: hydroxychloroquine;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Other: mass spectrometry;   Other: pharmacological study;   Procedure: biopsy
36 Recruiting Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Conditions: Cancer;   Myeloma;   Multiple Myeloma
Intervention: Drug: Bortezomib
37 Recruiting Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
38 Recruiting Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: aMILs;   Biological: Allogeneic Myeloma Vaccine
39 Recruiting AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: pharmacogenomic studies;   Other: liquid chromatography;   Other: mass spectrometry;   Drug: HDAC inhibitor AR-42
40 Recruiting Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: Autologous Stem Cell Transplant;   Drug: Fludarabine
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years